Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger

Shire's CEO says he sees scientific and technological advances as an opportunity to become the leading rare disease company. Ornskov also talked about the firm's debt-reduction and M&A strategy going forward.